首页|Developed by VHIO, a novel AI-based and non-invasive diagnostic tool enables acc urate brain tumor diagnosis, outperforming current classification methods
Developed by VHIO, a novel AI-based and non-invasive diagnostic tool enables acc urate brain tumor diagnosis, outperforming current classification methods
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News-Developed by VHIO, a novel AI-based and non-invasive diagnostic tool enables accurate brain tumor diagnosis, outperfor ming current classification methods Jointly developed by investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Radiomics Group and the Bellvitge University Hospital's Neuroradiology Un it, the Diagnosis in Susceptibility Contrast Enhancing Regions for Neuroncology (DISCERN) is an open access, deep learning tool based on the training of pattern s using artificial intelligence models from information of standard magnetic res onance imaging (MRI). Published in the journal Cell Reports Medicine*, results of a VHIO-led study demonstrate the feasibility and accuracy of DISCERN as an ena bler of accurate brain tumor diagnosis from perfusion MRI, outperforming convent ional methods.
Artificial IntelligenceEmerging TechnologiesHospitalsMachine LearningVall d'Hebron Institute of Oncology
NETL
NSTL
